C lozapine is a dibenzodiazapine antipsychotic drug that has a unique receptor binding profile and side effects. [1] [2] [3] It is the only antipsychotic medication that has proven efficacy and cost-effectiveness for treatment-resistant schizophrenia. [4] [5] [6] [7] [8] [9] Because of its superior efficacy, it has been widely used.
Clozapine-induced fever is a commonly reported phenomenon, [10] [11] [12] which often occurs within the first 4 weeks of treatment initiation. [10] [11] [12] The incidence of clozapine-induced fever varied widely from 0.5% to 50%, 4,10-16 depending on the study methodology. However, the topic did not receive as much attention as other side effects related to clozapine, albeit its relatively high incidence.
Risk factors associated with clozapine-induced fever were also being understudied, with limited literature exploring the topic. Therefore, in our study, we would like to study: the prevalence of clozapine-induced fever in our local unit, the sample characteristics of patients suffering from clozapine-induced fever, and the risk factors related to clozapine-induced fever.
Method
A retrospective chart review of all Chinese patients newly started on clozapine during their inpatient stay in a local hospital in Hong Kong from March 2003 to December 2006 was performed. The psychiatric unit in this study served a population of 0.8 million and provided general psychiatric service. Outpatients, patients discharged within 4 weeks after initiation of clozapine, and patients who had stopped using clozapine within 4 weeks were excluded. The occurrence of fever in the first 8 weeks after the start of clozapine was recorded for analysis. Fever was defined as any temperature at or above 38°C measured with a tympanic thermometer.
Demographic variables were retrieved from medical records for patients with and without clozapine-related fever. Physical examination findings and investigations performed were recorded to determine the cause of fever. Besides routine blood tests, chest X-ray, blood culture, and urine culture were performed. Nasopharyngeal aspirate was also performed in patients with rhinorrhoea to rule out respiratory viral infection, including infections by influenza A, influenza B, respiratory syncytial virus, and adenovirus.
All statistical analysis was done by SPSS 15.0 (SPSS Inc, Chicago, IL). Comparison of demographic and baseline data between subjects with and without clozapine-induced fever were analyzed using a chi-square test for categorical variables, and independent t test and Mann-Whitney U tests for parametric and nonparametric continuous variables. The Fisher exact test was used when a large sample approximation was inappropriate. Multivariate logistic regression was used to assess the simultaneous influence of different variables on the risk of developing clozapine-induced fever.
The study was approved by the hospital ethics committee.
Results
Medical records were retrieved for patients (n = 267) newly started on clozapine from March 2003 to December 2006 in our local unit. All patients were Chinese. Forty patients were excluded ( Figure 1 ). However, none of those excluded developed a fever higher than 38°C during the first 8 weeks of clozapine initiation and they had similar characteristics as the included subjects. In the final analysis, 227 patients were included. (1/41) . No investigations were performed in 2 of the patients, thus infections could not be ruled out. Thirty-one patients were considered to have clozapine-induced fever because of negative physical examination and investigation findings. The incidence of clozapine-induced fever in our study was therefore 13.7% (31/227).
In the 31 patients with clozapine-induced fever, 61.3% (19/31) were male and 38.7% (12/31) were female, aged 41.4, SD 11.5 years. The onset of fever after initiation of clozapine was 13.7, SD 7.1 days (range, 5 to 47 days). In all except one case, fever occurred within the first 3 weeks. The duration of fever was 4.7, SD 3.0 days (range, 1 to 12 days). The highest temperature of fever was 38.8°C, SD 0.5 (range, 38.0 to 39.8°C). Clozapine dosage at the onset of fever was 166.1, SD 73.2 mg/d (range, 50 to 300 mg/d). Eighteen (58.1%) of the patients had an elevated white cell count and 9.7% (3/31) of the patients had an elevated eosinophil count. None of the 31 patients developed neutropenia or agranulocytosis. One patient developed hypotension and another developed dehydration, which resolved spontaneously after clozapine was withdrawn. Twenty-four of the patients (77.4%) were given paracetamol and all showed symptomatic relief.
Clozapine was stopped in 45.2% (14/31) of the patients and fever subsided spontaneously within 48 hours in 79% of them. Clozapine re-challenge was performed in 7 patients and only one had recurrence of fever (14.3%).
Clinical characteristics between the patients with and without clozapine-induced fever were found to be different for the rate of clozapine titration (P < 0.01), bipolar affective disorder (P = 0.02), concomitant use of valproate (P = 0.01), and presence of any physical illness (P = 0.05) ( Table 1) . However, many patients with bipolar affective disorder were using valproate (76.9%). In the final multivariate logistic regression model, rate of clozapine titration more than 50 mg per week (OR 18.9; 95% CI 5.3 to 66.7; P < 0.01), concomitant use of valproate (OR 3.6; 95% CI 1.5 to 8.9; P = 0.01), and presence of physical illnesses (OR 3.2; 95% CI 1.2 to 8.3; P = 0.02) were found to predict the occurrence of clozapine-induced fever.
Discussion
In our study, the incidence of clozapine-induced fever was found to be 13.7%, which is lower than the incidence found in other systematic studies. [10] [11] [12] The difference in incidence probably resulted from our greater effort in detecting other causes of fever, including the detection of respiratory viral infection. Clozapine-induced fever is a common phenomenon as shown in our study. Other antipsychotics such as haloperidol 17 and olanzapine 18 were not found to be associated with fever. In our sample, only one among the 7 patients (14.3%) experienced recurrence of fever after clozapine re-challenge. Previous studies reported successful re-challenge in almost all patients. [10] [11] [12] [19] [20] We found that the rate of titration, concomitant use of valproate, and the presence of physical illnesses were associated with clozapine-induced fever. A previous study only found age to be a predictor for a clozapine-induced fever of 38.5 EC or higher. 10 We did not demonstrate a similar association in our study. In another study, no statistically significant predictor model emerged by studying 13 patients with clozapine-induced fever. 12 The differences might be accounted for by our larger sample size, meticulous exclusion of infections, and the difference in drug metabolism between Chinese and Caucasians. Asians and Caucasians were known to have significant difference in the enzymatic activity of several phase I liver enzymes such as CYP1A2, resulting in higher plasma concentration of drugs metabolized by these enzymes in Asians, when compared with Caucasians. 21 Plasma clozapine concentrations were reported to be higher in Chinese, compared with Caucasians at a similar
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The oral dose of clozapine. [22] [23] Thus Chinese patients may be more sensitive to rapid clozapine titration, as compared with Caucasians. Clozapine metabolism was also found to be affected by concomitant use of valproate, although the results had been contradicting. [24] [25] [26] [27] Our study suggests gradual titration of clozapine should be adopted, especially in patients with concomitant physical illness and valproate use.
The mechanism of clozapine-induced fever is unknown. Clozapine-induced fever was accompanied by more pronounced increases in TNF-á plasma levels, as well as by increases in the plasma levels of IL-6 and granulocyte colony-stimulating factor, and in granulocyte counts. 28 It was postulated that the increases in the plasma levels of cytokines and soluble cytokine receptors are pivotal towards the immune-mediated responses of clozapine, including clozapine-induced fever and agranulocytosis. 13, 28 When managing patients with clozapine-induced fever, investigations including complete blood picture, liver and renal function tests, blood culture, urine culture, chest X-ray, and creatine kinase should be performed. Nasopharyngeal aspirate can be useful in places where the prevalence of respiratory viral infection is high. Previous studies and reviews suggested that clozapine-induced fever is benign once infection and other medical causes are ruled out; clozapine should be continued, and the fever may be managed by antipyretic. 10, [29] [30] Our study was limited by its retrospective design and arbitrary definition of fever at 38°C, which might lead to possible underestimation of the incidence of clozapine-induced fever. Also, results from our study may not be generalizable to non-Chinese populations.
Conclusion
Clozapine-induced fever is common and occurs mostly during the first 3 weeks of clozapine initiation. Investigations should be done to exclude infection and other medical causes. A gradual rate of titration, especially in Chinese patients receiving valproate and suffering from physical illnesses may prevent clozapine-induced fever.
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Résumé : L'incidence et les caractéristiques de la fièvre induite par clozapine dans un service psychiatrique local de Hong Kong Objectif : Déterminer l'incidence, les caractéristiques, et les prédicteurs d'une fièvre induite par la clozapine dans un échantillon de patients d'un service psychiatrique local.
Méthode : Une étude rétrospective des notes au dossier de 227 patients hospitalisés récemment traités à la clozapine, de mars 2003 à décembre 2006, a été menée. Les caractéristiques démographiques, la présence de la fièvre, les investigations effectuées, les caractéristiques de la fièvre, et les complications de la fièvre ont été enregistrées et analysées. Les patients ayant une fièvre induite par la clozapine ont été comparés avec leurs homologues sans fièvre pour ce qui est des facteurs démographiques et cliniques. Une régression logistique multivariée a été exécutée pour identifier les prédicteurs de la fièvre induite par la clozapine.
Résultats :
Trente et un patients sur 227 (13,7 %) ont développé une fièvre induite par la clozapine. Les moyennes du nombre de jours où a débuté la fièvre après l'initiation de la clozapine et de la durée de la fièvre étaient de 13,7 et 4,7 jours, respectivement. La moyenne de la température corporelle la plus élevée était de 38,8°C. La fièvre se résorbait dans les 48 heures après l'interruption de la clozapine chez 79 % des patients ayant la fièvre induite par la clozapine. Un patient sur 7 (14,3 %) avait la fièvre à la reprise du traitement. La fièvre induite par la clozapine était associée à un taux de titrage supérieur à 50 mg/semaine (OR 18,9; 95 % IC 5,3 à 66,7; P < 0,01), à l'utilisation concomitante de valproate (OR 3,6; 95 % IC 1,5 à 8,9; P = 0,01), et à la présence de maladies somatiques (OR 3,2; 95 % IC 1,2 à 8,3; P = 0,02).
Conclusion :
La fièvre induite par la clozapine est fréquente. Le retrait temporaire de la clozapine peut faire disparaître la fièvre, et la reprise du traitement à la clozapine peut être envisagée après que la fièvre disparaît. Un taux de titrage plus lent de la clozapine peut être utile chez les patients souffrant de maladie somatique sous-jacente ou recevant un traitement concomitant de valproate.
